Search

Corporate Sponsor Program

View the EHA Ranking 2025

"Alone we can do so little; together we can do so much.

Read more

HARMONY: Innovative Medicines Initiative approves € 40 million project for better care of patients with hematologic malignancies

HARMONY will capture, integrate, analyze and harmonize anonymous patient data from high-quality multidisciplinary sources to unlock valuable knowledge on multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), myelodysplastic syndromes (MDS)…

Read more

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

Annual reports

EHA Annual Report 2023You can access an interactive version of our most recent annual report using the link below. Read the EHA Annual Report 2023

Previous annual reportsYou can read annual reports from previous years as PDFs.

Read more

David Grimwade Award

In 2017, EHA established a new award in honor of the late David Grimwade, for his great involvement and contribution to the European Hematology Association and its scientific activities as Board Member, TRTH Co-Director and Chair of the Scientific Program…

Read more

Report Drug Shortages to EHA

In an effort to mitigate shortages of hematologic drugs in Europe, EHA is collecting and compiling reports of shortages. Are you experiencing, or foreseeing drug shortages in your clinical practice?

Please report those to drugshortage@ehaweb. org.

Read more

Restrictions

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed.

Read more